Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus - PubMed (original) (raw)
Randomized Controlled Trial
. 2007 Aug;50(8):1723-31.
doi: 10.1007/s00125-007-0698-9. Epub 2007 May 23.
Affiliations
- PMID: 17520238
- DOI: 10.1007/s00125-007-0698-9
Randomized Controlled Trial
Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus
M Bajaj et al. Diabetologia. 2007 Aug.
Abstract
Aims/hypothesis: The aim of the study was to examine the effects of pioglitazone (PIO), a peroxisome proliferator-activated receptor (PPAR)-gamma agonist, and fenofibrate (FENO), a PPAR-alpha agonist, as monotherapy and in combination on glucose and lipid metabolism.
Subjects and methods: Fifteen type 2 diabetic patients received FENO (n = 8) or PIO (n = 7) for 3 months, followed by the addition of the other agent for 3 months in an open-label study. Subjects received a 4 h hyperinsulinaemic-euglycaemic clamp and a hepatic fat content measurement at 0, 3 and 6 months.
Results: Following PIO, fasting plasma glucose (FPG) (p < 0.05) and HbA(1c) (p < 0.01) decreased, while plasma adiponectin (AD) (5.5 +/- 0.9 to 13.8 +/- 3.5 microg/ml [SEM], p < 0.03) and the rate of insulin-stimulated total-body glucose disposal (R (d)) (23.8 +/- 3.8 to 40.5 +/- 4.4 micromol kg(-1) min(-1), p < 0.005) increased. After FENO, FPG, HbA(1c), AD and R (d) did not change. PIO reduced fasting NEFA (784 +/- 53 to 546 +/- 43 micromol/l, p < 0.05), triacylglycerol (2.12 +/- 0.28 to 1.61 +/- 0.22 mmol/l, p < 0.05) and hepatic fat content (20.4 +/- 4.8 to 10.2 +/- 2.5%, p < 0.02). Following FENO, fasting NEFA and hepatic fat content did not change, while triacylglycerol decreased (2.20 +/- 0.14 to 1.59 +/- 0.13 mmol/l, p < 0.01). Addition of FENO to PIO had no effect on R (d), FPG, HbA(1c), NEFA, hepatic fat content or AD, but triacylglycerol decreased (1.61 +/- 0.22 to 1.00 +/- 0.15 mmol/l, p < 0.05). Addition of PIO to FENO increased R (d) (24.9 +/- 4.4 to 36.1 +/- 2.2 micromol kg(-1) min(-1), p < 0.005) and AD (4.1 +/- 0.8 to 13.1 +/- 2.5 microg/ml, p < 0.005) and reduced FPG (p < 0.05), HbA(1c) (p < 0.05), NEFA (p < 0.01), hepatic fat content (18.3 +/- 3.1 to 13.5 +/- 2.1%, p < 0.03) and triacylglycerol (1.59 +/- 0.13 to 0.96 +/- 0.9 mmol/l, p < 0.01). Muscle adenosine 5'-monophosphate-activated protein kinase (AMPK) activity did not change following FENO; following the addition of PIO, muscle AMPK activity increased significantly (phosphorylated AMPK:total AMPK ratio 1.2 +/- 0.2 to 2.2 +/- 0.3, p < 0.01).
Conclusions/interpretation: We conclude that PPAR-alpha therapy has no effect on NEFA or glucose metabolism and that addition of a PPAR-alpha agonist to a PPAR-gamma agent causes a further decrease in plasma triacylglycerol, but has no effect on NEFA or glucose metabolism.
Similar articles
- Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
Balasubramanian R, Gerrard J, Dalla Man C, Firbank MJ, Lane A, English PT, Cobelli C, Taylor R. Balasubramanian R, et al. Diabet Med. 2010 Feb;27(2):150-6. doi: 10.1111/j.1464-5491.2009.02906.x. Diabet Med. 2010. PMID: 20546257 - Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients.
Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA. Bajaj M, et al. Int J Obes Relat Metab Disord. 2004 Jun;28(6):783-9. doi: 10.1038/sj.ijo.0802625. Int J Obes Relat Metab Disord. 2004. PMID: 15024400 - Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M. Sathyanarayana P, et al. Obesity (Silver Spring). 2011 Dec;19(12):2310-5. doi: 10.1038/oby.2011.152. Epub 2011 Jun 9. Obesity (Silver Spring). 2011. PMID: 21660077 Clinical Trial. - Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
Derosa G, Maffioli P. Derosa G, et al. Curr Mol Pharmacol. 2012 Jun;5(2):272-81. doi: 10.2174/1874467211205020272. Curr Mol Pharmacol. 2012. PMID: 22122457 Review. - PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Wilding JP. Wilding JP. Diabetes Obes Metab. 2012 Nov;14(11):973-82. doi: 10.1111/j.1463-1326.2012.01601.x. Epub 2012 Apr 23. Diabetes Obes Metab. 2012. PMID: 22443197 Review.
Cited by
- Impact of pemafibrate on lipid profile and insulin resistance in hypertriglyceridemic patients with coronary artery disease and metabolic syndrome.
Nakamura A, Kagaya Y, Saito H, Kanazawa M, Sato K, Miura M, Kondo M, Endo H. Nakamura A, et al. Heart Vessels. 2024 Jun;39(6):486-495. doi: 10.1007/s00380-024-02363-z. Epub 2024 Feb 23. Heart Vessels. 2024. PMID: 38393377 Clinical Trial. - Targeting lipid-sensing nuclear receptors PPAR (α, γ, β/δ): HTVS and molecular docking/dynamics analysis of pharmacological ligands as potential pan-PPAR agonists.
Mandal SK, Puri S, Kumar BK, Muzaffar-Ur-Rehman M, Sharma PK, Sankaranarayanan M, Deepa PR. Mandal SK, et al. Mol Divers. 2024 Jun;28(3):1423-1438. doi: 10.1007/s11030-023-10666-y. Epub 2023 Jun 6. Mol Divers. 2024. PMID: 37280404 - Molecular dynamics articulated multilevel virtual screening protocol to discover novel dual PPAR α/γ agonists for anti-diabetic and metabolic applications.
Mandal S, Faizan S, Raghavendra NM, Kumar BRP. Mandal S, et al. Mol Divers. 2023 Dec;27(6):2605-2631. doi: 10.1007/s11030-022-10571-w. Epub 2022 Nov 28. Mol Divers. 2023. PMID: 36437421 - Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes.
Moody AJ, Molina-Wilkins M, Clarke GD, Merovci A, Solis-Herrera C, Cersosimo E, Chilton RJ, Iozzo P, Gastaldelli A, Abdul-Ghani M, DeFronzo RA. Moody AJ, et al. Diabetes Obes Metab. 2023 Feb;25(2):426-434. doi: 10.1111/dom.14885. Epub 2022 Nov 4. Diabetes Obes Metab. 2023. PMID: 36204991 Free PMC article. - Beneficial Effect of Fenofibrate and Silymarin on Hepatic Steatosis and Gene Expression of Lipogenic and Cytochrome P450 Enzymes in Non-Obese Hereditary Hypertriglyceridemic Rats.
Vecera R, Poruba M, Hüttl M, Malinska H, Oliyarnyk O, Markova I, Racova Z, Soukop J, Kazdova L. Vecera R, et al. Curr Issues Mol Biol. 2022 Apr 26;44(5):1889-1900. doi: 10.3390/cimb44050129. Curr Issues Mol Biol. 2022. PMID: 35678658 Free PMC article.
References
- J Biol Chem. 2003 May 16;278(20):17982-5 - PubMed
- Nat Med. 2002 Nov;8(11):1288-95 - PubMed
- Am J Physiol Endocrinol Metab. 2003 Mar;284(3):E531-40 - PubMed
- Diabetes. 2004 Aug;53(8):2169-76 - PubMed
- Diabetologia. 2004 May;47(5):816-20 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous